Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | DGKZ | Q13574 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29311431 | 0.83 | PDE3B (0.44) | GRM2CYP1A2ADORA2B | |
| SCHEMBL28659735 | 0.77 | PDE4A (0.41) | GRM2ADORA2APDE4APDE4BPDE4C | |
| SCHEMBL29310486 | 0.77 | ADORA2B (0.38) | ADORA2BDGKZ | |
| SCHEMBL29311703 | 0.72 | PIK3CA (0.41) | ADORA2APDE4BPDE4DDGKZ | |
| SCHEMBL27252322 | 0.71 | GSK3B (0.37) | ADORA2APDE4BPDE4DDGKZ | |
| SCHEMBL29310609 | 0.70 | GSK3B (0.36) | ADORA2APDE4BPDE4DDGKZ | |
| SCHEMBL27266102 | 0.70 | PTGER4 (0.51) | GRM2CYP1A2ADORA2APDE4APDE4B | |
| SCHEMBL24390568 | 0.69 | PDE10A (0.48) | CYP1A2ADORA2APDE4APDE4BPDE4C | |
| SCHEMBL27780814 | 0.69 | CDK4 (0.46) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19231460 | 0.68 | CDC7 (0.44) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | GRM2 4674/4885CYP1A2 1091/4885ADORA2A 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.